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SPECIAL ARTICLE
The expanded spectrum of neuromyelitis 
optica – evidences for a new definition 
O espectro expandido da neuromielite óptica – as evidências para nova definição
Marco A. Lana-Peixoto1, Dagoberto Callegaro2 
Association of optic neuritis and myelitis was first de-
scribed by Giovanni Battista Pescetto in Italy, in 18441. Few 
other cases were reported until 1894 when Eugène Devic 
published his own case2, and along with his student, Fernand 
Gault, reviewed 16 others they found in the literature, pro-
viding a systematic description of the disease3. For over 100 
years, the terms neuromyelitis optica (NMO) and Devic’s 
disease were employed to identify patients with a condition 
considered as a variant of multiple sclerosis (MS), in which 
symptoms were confined to the optic nerves and spinal cord, 
occurred either simultaneously or within an interval of few 
weeks, and most frequently had a poor outcome4.
In the last few years, however, the traditional concept of NMO 
has dramatically changed as a result of clinical analysis of larger 
cohorts, magnetic resonance imaging (MRI) studies that charac-
terized acute transverse myelitis as longitudinally extensive spinal 
cord lesions (LESCL) and disclosed asymptomatic brain lesions in 
most patients, pathological and immunopathological evidences 
that suggested predominant humoral autoimmune response, and 
finally discovery of NMO-IgG and aquaporin-4 (AQP4) as a spe-
cific biomarker of the disease and its targeted antigen.
Currently, NMO is considered as a central nervous system 
(CNS) AQP4 channelopathy which causes variable damage 
predominantly to the optic nerves and spinal cord, although 
other CNS structures that highly express AQP4 may be also af-
fected. Identification of the specific antibody in limited pheno-
typic presentation of the disease and the frequent association 
of optic neuritis and myelitis with other systemic autoimmune 
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ABSTRACT
Neuromyelitis optica (NMO) has been traditionally described as the association of recurrent or bilateral optic neuritis and longitudinally ex-
tensive transverse myelitis (LETM). Identification of aquaporin-4 antibody (AQP4-IgG) has deeply changed the concept of NMO. A spectrum of 
NMO disorders (NMOSD) has been formulated comprising conditions which include both AQP4-IgG seropositivity and one of the index events 
of the disease (recurrent or bilateral optic neuritis and LETM). Most NMO patients harbor asymptomatic brain MRI lesions, some of them 
considered as typical of NMO. Some patients with aquaporin-4 autoimmunity present brainstem, hypothalamic or encephalopathy symp-
toms either preceding an index event or occurring isolatedly with no evidence of optic nerve or spinal involvement. On the opposite way, other 
patients have optic neuritis or LETM in association with typical lesions of NMO on brain MRI and yet are AQP4-IgG seronegative. An expanded 
spectrum of NMO disorders is proposed to include these cases.  
Key words: neuromyelitis optica spectrum disorders, optic neuritis, longitudinally extensive tranverse myelitis, brainstem, hypothalamus, 
encephalopathy, MRI, antiaquaporin-4 antibody.
RESUMO
Neuromielite óptica (NMO) tem sido tradicionalmente caracterizada como associação de neurite óptica recorrente ou bilateral e mielite 
tranversa longitudinalmente extensa (MTLE). O conceito de NMO tem mudado desde a identificação do anticorpo antiaquaporina-4. A NMO 
é atualmente considerada como um espectro de condições contendo pelo menos um dos eventos índices da doença (neurite óptica recor-
rente ou bilateral e MTLE) e soropositividade para AQP4-IgG. A maioria dos pacientes apresenta lesões cerebrais à imagem por ressonância 
magnética (IRM), algumas delas típicas de NMO. Pacientes soropositivos podem desenvolver sintomas de tronco encefálico, hipotálamo e de 
encefalopatia precedendo os eventos índices, ou isoladamente, na ausência de qualquer evidência de alteração visual ou espinal. Por outro 
lado, há pacientes soronegativos que apresentam ou neurite óptica ou MTLE associada a lesões cerebrais típicas de NMO à IRM. Todas essas 
situações estão incluídas no espectro expandido de NMO aqui proposto.
Palavras-Chave: espectro de neuromielite óptica, neurite óptica, mielite transversa longitudinalmente extensa, tronco encefálico, 
hipotálamo, encefalopatia, IRM, anticorpo antiaquaporina-4.
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diseases have led to the view of NMO as a spectrum of CNS 
disorders. As further experience, making use of more refined 
AQP4-IgG assays and testing serum from patients with atypi-
cal clinical features continuously increases the observed vari-
ability of clinical manifestations at disease onset and during its 
course broadens. This suggests that periodical revisions of es-
tablished concepts and diagnostic criteria are necessary.
This paper aimed to analyze the current concept of the 
spectrum of NMO and to show evidences that support its re-
vision. It also proposed an expanded definition of the spec-
trum of NMO as a framework for building new diagnostic cri-
teria for the condition. 
DIAGNOSTIC CRITERIA FOR NEUROMYELITIS OPTICA
Throughout the last century, as the number of reports on 
patients with the association of optic neuritis and myelitis in-
creased, authors in both Western and Eastern countries were 
concerned with formulation of diagnostic criteria for NMO in 
order to guiding practitioners and providing researchers with 
a common ground for communicating their observations3,5-7. 
Although some of the proposed diagnostic criteria accepted 
attack recurrences7, all of them required absence of signs of 
brain involvement, except for “minor brainstem symptoms”. 
Following incorporation of MRI into clinical practice, some 
authors included negative brain MRI as a requirement for 
diagnosis6 whereas others7 contemplated the diagnosis of 
NMO even in patients with brain lesions “which would be 
unexpected in multiple sclerosis” (Table 1).  
By the end of the twentieth century, a review of a large co-
hort at Mayo Clinic8 showed that (1) optic neuritis in NMO 
patients might be unilateral or bilateral; (2) the interval over 
which patients developed the disease index events (optic neuri-
tis and myelitis) had no diagnostic significance; (3) the majority 
of patients had a relapsing course; (4) the clinical manifestations 
were frequently severe; (5) cerebrospinal fluid (CSF) abnormali-
ties were characterized by neutrophilic pleocytosis or a greater 
number of nucleated cells usually associated with negative oli-
goclonal bands; (6) abnormal signal on spinal cord MRI extend-
ed over ≥3 vertebral segments; and (7) brain MRI was either nor-
mal or showed unspecific lesions. These features could promptly 
help to distinguish NMO from MS and were used, therefore, for 
formulation of the 1999 diagnostic criteria for NMO8 (Table 2).
The discovery of the NMO-specific antibody in 20049 and of 
AQP4, as its targeted antigen in the following year10, is recog-
nized as a turning point in the concept and understanding of 
the disease. Aquaporin-4 is the most abundant water channel 
in the central nervous system, expressed in the foot process-
es of astrocytes in contact with blood vessels throughout the 
brain, spinal cord and optic nerves. The periventricular area, 
the hypothalamus and the brainstem are also considered sites 
of high expression of AQP-4. It is particularly concentrated un-
derlying the pia mater and the ependymal cells in contact with 
the CSF, and its expression is critical for normal regulation of 
water flux at the blood-brain barrier and CSF-brain interfac-
es11. Although AQP-4 predominates in the CNS, it is also found 
in other organs such as the kidneys, stomach, airways, glands 
and skeletal muscle12. However, the paucity of clinical abnor-
malities outside the CNS remains to be explained.
Discovery of AQP4-IgG as a sensitive and highly specific 
serum biomarker for NMO provided a sound basis to incor-
porate its serum detection in the 2006 revised diagnostic cri-
teria (Table 3)13.  
B: bilateral; U: unilateral; S: simultaneous; Mos: months; Yrs: years; M: monophasic; R: relapsing; NI: not informed; OB: oligoclonal bands; Br: brain; SC: spinal 
cord; N: normal; Abn: abnormal; LSCL: long spinal cord lesion; CSF: cerebrospinal fluid; MRI: magnetic resonance imaging.
Author (y) Optic neuritis Myelitis Interval Monophasic/Relapsing Brain symptoms CSF MRI
Devic/Gault (1894)3 B Acute S M Rare
Shibasaki et al. 
(1981) 5 B Acute S M No
Mandler et al. 
(1993)6 U/B Acute S/Mos–Yrs NI No No OB
Br: normal
SC: cavitation
O’Riordan et al. 
(1996)7 U/B
Severe 
transverse Mos-Yrs M/R No Rare OB
Br: N/Abn
SC: usually LSCL
Table 1. Diagnostic criteria for neuromyelitis optica prior to 1999.
Table 2. Wingerchuk’s 1999 diagnostic criteria for neuromyelitis optica8.
Absolute criteria (all required)
Supportive criteria (either 1 major criterion or 2 minor criteria)
Major supportive criteria Minor supportive criteria
Optic neuritis
Acute myelitis
No evidence of clinical disease outside of 
the optic nerve and spinal cord
Negative brain MRI at onset (does not meet Paty 
radiological criteria for MS)
Spinal cord MRI with signal abnormality 
extending over >3 vertebral segments
CSF pleocytosis of >50 WBC/mm3 OR >5 
neutrophils/mm3
Bilateral optic neuritis
Severe optic neuritis with fixed VA worse 
than 20/200 in at least one eye
Severe, fixed, attack-related weakness 
(MRC grade <2) in one or more limbs
CSF: cerebrospinal fluid; MRI: magnetic resonance imaging; WBC: white blood cells; VA: visual activity; MRC: Medical Research Council scale.
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CURRENT DEFINITION OF SPECTRUM OF 
NEUROMYELITIS OPTICA
Aquaporin-4 IgG seropositivity status in patients whose 
clinical features do not meet current diagnostic criteria for def-
inite NMO has led to the recognition of the disease as a spec-
trum of CNS AQP4 autoimmune disorders rather than a well-
defined restrictive condition in which occurrence of both optic 
neuritis and acute transverse myelitis is an absolute requisite 
for NMO diagnosis13. As a matter of fact, 19–31% of seroposi-
tive patients had the limited form of NMO14-16, and in one study 
20% of the seropositive patients did not fulfill the 2006 diagnos-
tic criteria even over ten years following disease presentation17. 
Current definition of spectrum of NMO disorders encom-
passes conditions in patients who have in addition to serum an-
ti-AQP4 antibodies at least one of the key clinical elements for 
diagnosis of NMO (idiopathic myelitis extending over ≥3 verte-
bral segments, or bilateral simultaneous or recurrent optic neu-
ritis)18.  It also recognizes the association of optic neuritis or lon-
gitudinally extensive transverse myelitis (LETM) with systemic 
autoimmune disorders, as well as with brain MRI lesions that 
are now considered as typical of neuromyelitis optica (Table 4)18. 
Requirement of AQP4 seropositivity status as a 
pitfall for the definition of neuromyelitis spectrum 
disorders (NMOSD)
As the current concept of NMOSD is based on the con-
comitance of AQP4-IgG seropositive status and one of the in-
dex events lacks of, any of these requisites rules out the diag-
nosis. On the other hand, it has been observed that even the 
NMO: neuromyelitis optica; MRI: magnetic resonance imaging.
Definite NMO
Optic neuritis
Acute myelitis
At least two of three supportive criteria
1. Contiguous spinal cord MRI lesion extending over ≥3 
vertebral segments
2. Brain MRI not meeting diagnostic criteria for multiple 
sclerosis
3. NMO-IgG seropositive status
Table 3. Revised diagnostic criteria for neuromyelitis optica, 200613.
most refined AQP4-IgG assays fail to detect serum antibod-
ies in a proportion of patients who fulfill the revised diagnos-
tic criteria for NMO. Although the underlying mechanisms of 
AQP4-IgG seronegative status in these patients remain to be 
clarified, presumed reasons include suboptimal sensitivity of 
the currently available assays, very low serum concentration 
of the antibodies or their absence at some periods in the dis-
ease course, and the inhibitory effect of previous treatment 
with corticosteroids or immunosuppressive agents19. It is also 
possible that in some NMO patients other antigens may play 
a role in the pathogenesis of the disease18,20. Therefore, not-
withstanding a positive serum AQP4-IgG test is of utmost im-
portance for the diagnosis of NMOSD, a negative result alone 
cannot rule out the diagnosis.   
Aquaporin 4-IgG assays
Serum AQP4-IgG can be detected in the sera of NMO 
patients by a variety of techniques21. The antibody was first 
identified among 102 North American patients with NMO or 
syndromes that suggest high risk of NMO and 12 Japanese 
patients with optic-spinal multiple sclerosis (OSMS) by in-
direct immunofluorescence with a composite substrate of 
mouse tissues9. Sensitivity and specificity were 73 and 91% 
for NMO and 58 and 100% for OSMS, whereas the antibody 
was found in 50% of patients with high-risk syndromes9. The 
serum antibody has been variably detected in different popu-
lations22. Currently available assays include a tissue-based in-
direct immunofluorescence (IIF) assay; ELISA; fluorescence 
immunoprecipitation assay (FIPA)23,24; fluorescence-activat-
ed cell sorting (FACS) assay; and visual fluorescence-ob-
servation cell-based assay (CBA)24-26. A recent internation-
al comparative study of the different techniques to detect 
AQP4-IgG in sera of patients with NMO and NMOSD showed 
that, although their specificities were excellent, their sen-
sitivities were variable27. Whereas the most sensitive tech-
niques were human AQP4-transfected cell-based assays (73–
77%), fluorescence immunoprecipitation assay (FIPA) and 
the mouse tissue-based indirect immunofluorescence assay 
were the least sensitive (around 50%)27. The commercial-
ly introduced ELISA which is a simple and relatively sensi-
tive technique may make AQP4-IgG serum assessment more 
widely available28. 
Requirement of optic neuritis or myelitis 
presence as a pitfall for the definition of 
neuromyelitis spectrum disorders 
Requirement of presence of either optic neuritis or 
LETM is a second pitfall in the current definition of 
NMOSD. It has been now well established that brain symp-
toms are not only frequent during disease course (Table 
5), but may antedate optic neuritis or acute transverse 
myelitis for months or years17,29. Incoercible vomiting and 
hiccups result from involvement of the area postrema at 
the floor of the fourth ventricle. In addition to being the MRI: magnetic resonance imaging.
Neuromyelitis optica
Limited forms of neuromyelitis optica
• Idiopathic single or recurrent events of longitudinally 
extensive myelitis (≥3 vertebral segment spinal cord 
lesion seen on MRI)
• Optic neuritis: recurrent or simultaneous bilateral
Asian optic-spinal multiple sclerosis
Optic neuritis or longitudinally extensive myelitis associated with 
systemic autoimmune disease
Optic neuritis or myelitis associated with brain lesions typical 
of neuromyelitis optica (hypothalamic, corpus callosal, 
periventricular, or brainstem)
Table 4. Neuromyelitis optica spectrum18.  
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vomiting reflex center27, area postrema also plays an im-
portant role in the regulation of blood pressure, cerebral 
blood flow and osmolarity30,31. This region highly express-
es AQP432-35 and is more susceptible to frequent attacks 
by anti-AQP4 antibodies as it lacks blood-brain barrier. 
Intractable hiccups, nausea and vomiting are the most fre-
quent brain symptoms in NMO, preceding and accompa-
nying optic neuritis or acute myelitis36. 
A number of hypothalamic symptoms, such as narco-
lepsy with decreased hypocretin-1 CSF level, anorexia and 
weight loss, hyperphagia and obesity, hypothermia or fe-
ver of unknown etiology, syndrome of inappropriate secre-
tion of antidiuretic hormone, diffuse anhydrosis, bradycar-
dia and hypotension, as well as recurring episodes of coma, 
have all been described in association with NMOSD32,37-41. 
Interestingly, enough in some patients, these symptoms 
have been observed preceding optic neuritis or myelitis, 
whereas in others they occurred in association with both 
AQP4-IgG seropositivity and hypothalamic abnormalities 
on brain MRI, but with no subsequent development of optic 
neuritis or myelitis40-43.   
Symptoms of encephalopathy may also occur in patients 
with established diagnosis of NMO or may in some patients 
precede the onset of optic neuritis or myelitis. Development 
of posterior reversible encephalopathy syndrome (PRES) in 
NMO patients has been ascribed to occurrence of transient 
vasogenic edema in areas with increased blood-brain per-
meability as a result of disruption of the normal water flux 
due AQP4 autoimmunity. Symptoms of PRES include confu-
sion, decreased consciousness and coma, ocular movement 
disturbances, retrochiasmal visual field defects and cortical 
blindness, seizures and aphasia44,45.   
Decreased mental status, impairment of consciousness, 
confusion and seizures have been reported as presenting 
symptoms of AQP4 autoimmunity. Optic neuritis or myelitis 
followed the cerebral symptoms at a variable time interval 
ranging from 3 to 110 months41,46,47.  
Typical brain MRI lesions in neuromyelitis optica
Following identification of AQP4-IgG, it was observed 
that 60% of the NMO patients presented signal abnormalities 
on brain MRI. Most of these abnormalities were non-specific 
lesions, 10% were multiple sclerosis-like lesions and 8% were 
lesions atypical of MS32. Although NMO MRI lesions may ful-
fill the current MS spatial dissemination criteria48, subse-
quent studies have further characterized the MRI findings in 
NMO patients, showing distinctive features which help to dif-
ferentiate NMOSD brain lesions from those characteristically 
found in MS patients49-55. 
The most distinctive brain lesions found on MRI of pa-
tients with NMOSD are listed below and illustrated by exam-
ples in Figure:
1. Extensive and confluent hemispheric white matter le-
sions which may be edematous, tumefactive and have 
a radial-shaped or spindle-like form. These lesions may 
shrink or disappear in subsequent studies.
2. Corticospinal tract lesions, frequently bilateral, involving 
the posterior limb of the internal capsule and the cerebral 
peduncle, which are usually longitudinally extensive fol-
lowing the pyramidal tract from subcortical area to the 
mesencephalon or pons. 
3. Gadolinium-enhanced lesions with heterogeneous inten-
sity and poor-defined borders (cloud-like lesions).
4. Lesions localized at sites of high AQP4 expression, such 
as the hypothalamus, and the ependymal surface around 
the third ventricle, aqueduct and fourth ventricle.
5. Lesions lining the ependymal surface of the lateral ven-
tricles, sometimes involving the corpus callosum or the 
cerebrum.
6. Large edematous and heterogenous lesions in the corpus 
callosum, with higher intensity in the rim and lower in 
the core (marble-like lesions) in the acute phase, and re-
duction in their size and intensity, or its disappearance in 
the chronic phase. 
7. Brainstem lesions that most frequently involve its central 
and dorsal aspects, including area postrema and nucleus 
tractus solitarius. These lesions may be associated with 
intractable vomiting and hiccups and may extend cau-
dally to the upper cervical spinal cord.
Unspecific white matter lesions have been described 
on brain MRI in 68% of NMO patients and on conventional 
Table 5. Brain symptoms in neuromyelitis optica
Brainstem symptoms
• Hiccups
• Nausea, vomiting
• Vertigo
• Dysarthria, dysphagia
• Ataxia
• Ocular movement disorders
• Facial paralysis
• Facial pain or dysesthesia
• Hearing loss, tinnitus
Hypothalamic symptoms
• Narcolepsy and other sleep 
disorders
• Anorexia and weight loss
• Hyperphagia and obesity
• Disturbances of body 
temperature
• Anhydrosis
• Inappropriate secretion of 
antidiuretic hormone syndrome
• Hypotension
• Bradycardia
• Excessive sweating
• Symptoms of hypopituitarism
• Presyncopal symptoms
• Recurrent coma
Cortical/subcortical 
symptoms
• Posterior reversible 
encephalopathy syndrome
• Aphasia
• Seizures
• Disturbances of consciousness
• Psychiatric symptoms
• Cognitive symptoms
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Figure. Typical brain magnetic resonance imaging in neuromyelitis optica. (A) Extensive edematous white matter lesion. 
(B) Tumefactive frontal lobe lesion. (C) Bilateral lesions in the posterior limb of the internal capsule. (D) Cloud-like gadolinium-
enhanced lesion. (E) Heterogeneous extensive callosal lesion. (F) Bilateral lesions in the hypothalamus. (G) Large mesencephalic 
lesion. (H) Lesion involving area postrema. (I) Central brainstem lesion. 
MRI they do not differ from those found in MS patients32. 
However, a recent study showed that, by making use of 7-T 
MRI scans, these unspecific lesions as seen on conventional 
MRI are quite distinct in NMOSD and MS56. They differ with 
regard to their location and expression of a hypointense rim. 
Whereas 92% of the MS plaques are centered by a small vein 
and express a hypointense rim, only one third of the white 
matter lesions in NMOSD have perivascular localization. 
Additionally, they rarely show the characteristic hypointense 
rim. A further differential feature between NMOSD and MS 
was the failure to find cortical lesions in NMOSD, as opposed 
to identification of lesions at this location in over one-half of 
the MS patients56.  
The strict and the expanded concept of the 
spectrum of neuromyelitis optica 
The continued advances in the understanding of the NMO 
pathophysiology, the use of more refined MRI techniques and 
the development of more sensitive anti-AQP4 antibody assays 
associated and their broader availability to investigators around 
the world have all led to a rapid and deep change in the con-
cept of the spectrum of NMO. The identification of a large num-
ber of patients with AQP4-IgG seropositive status who do not 
meet the 2007 definition of NMOSD suggests that a wider range 
of clinical phenotypic presentations have to be included in an 
expanded spectrum of NMO. The increasing number of report-
ed “atypical NMO cases” or of patients with “cerebral aquaporin 
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MRI: magnetic resonance imaging; AQP4: aquaporin-4.
Conditions with at least 1 of the following:
• Single, recurrent or simultaneous bilateral optic neuritis 
• Longitudinally extensive myelitis ( ≥3 vertebral segments) 
• Recurrent brainstem symptoms
• Recurrent hypothalamic symptoms
• Recurrent cerebral symptoms
Plus at least 1 of the following:
• Positive AQP4-IgG serum status
• Brain MRI lesions typical of neuromyelitis optica
Table 6. Expanded spectrum of neuromyelitis optica autoimmunity” in whom AQP4-IgG seropositive status is as-
sociated with symptoms of encephalopathy, hypothalamic or 
brainstem involvement, either preceding for months or years 
the development of myelitis or optic neuritis, or occurring as an 
isolated clinical phenomenon — i.e., with no past or present evi-
dences of optic neuritis or myelitis — suggests that the 2007 def-
inition of the spectrum of NMO is in need of expansion.  
Optic neuritis and acute transverse myelitis usually have 
well-defined characteristics in patients with definite NMO. 
Most frequently, optic neuritis is recurrent or simultaneous-
ly occurs on both sides, severely affects the visual functions 
and may respond poorly to corticosteroid treatment. On its 
turn, acute transverse myelitis in NMO is typically longitudi-
nally extensive and preferentially affects the central part of 
the cord or its entire diameter, showing an edematous tume-
factive aspect in the acute phase. Only in few cases these fea-
tures cannot distinguish optic neuritis and acute transverse 
myelitis found in NMOSD from those occurring in MS or oth-
er conditions55-57. In these instances, appropriate workup in-
cluding brain MRI, CSF analysis, as well as specific tests for 
other conditions, help to define the diagnosis.
The finding of AQP4-IgG seropositive status in patients 
with recurrent or simultaneous bilateral optic neuritis or 
with LETM would make them meet present definition of 
NMOSD. However, the majority of patients who develop 
these symptoms are AQP4-IgG seronegative by currently 
available assays and, therefore, do not fulfill the accepted 
definition of spectrum of NMO. Some of them will present a 
second index event of the disease later on and may even con-
vert to seropositive status during the course of their disease. 
Likewise, patients with cerebral symptoms not associated 
with recurrent optic neuritis or LETM will not be included in 
the current spectrum of NMO notwithstanding the possibil-
ity of their being AQP4-IgG seropositive or having brain MRI 
lesions typical of NMO. 
It would be highly desirable if all these patients could be 
recognized as part of an expanded spectrum of NMO as pro-
phylactic treatment may preserve them from a subsequent 
and potentially disabling attack of the disease. Brain MRI le-
sions typical of NMO may be considered as an alternate sup-
portive evidence for the diagnosis of NMOSD in patients with 
recurrent optic neuritis, LETM, recurrent brainstem, hypo-
thalamic or encephalopathy symptoms, and AQP4-IgG sero-
negative status (Table 6). 
Although this proposed expanded spectrum of NMO in-
corporates some non-conventional presentations of the dis-
ease, the full phenotypic components of the disease spec-
trum remain to be identified through better understanding 
of its immunopathogenetic mechanisms and development of 
more sensitive biomarkers. 
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